Non-Operating Income/Expense (Quarterly)

Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.

Alnylam Pharmaceuticals, Inc. (ALNY) had Non-Operating Income/Expense of $-46.98M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$1.17B
Net Income	$205.99M
Cost of Goods Sold	$211.12M
Gross Profit	$956.05M
Operating Expenses	$898.54M
Operating Income	$268.64M
Non-Operating Income/Expense	$-46.98M
Pre-Tax Income	$221.65M
Normalized Pre-Tax Income	$221.65M
Income after Taxes	$205.99M
Income from Continuous Operations	$205.99M
Consolidated Net Income/Loss	$205.99M
Normalized Income after Taxes	$205.99M
EBIT	$268.64M
EBITDA	$282.19M
Weighted-Average Shares Outstanding (Basic)	132.89M
Weighted-Average Shares Outstanding (Diluted)	138.23M
Earnings per Share (EPS) (Basic)	$1.55
Earnings per Share (EPS) (Diluted)	$1.51
Balance Sheet Financials
Current Assets	$4.22B
Property, Plant, and Equipment	$518.26M
Long-Term Assets	$910.24M
Total Assets	$5.13B
Current Liabilities	$1.35B
Long-Term Debt	$1.01B
Long-Term Liabilities	$2.70B
Total Liabilities	$4.05B
Common Equity	$1.08B
Tangible Shareholders Equity	$1.08B
Shareholders Equity	$1.08B
Common Shares Outstanding	133.44M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$70.50M
Cash Flow from Investing Activities	$-25.54M
Cash Flow from Financial Activities	$15.71M
Beginning Cash	$1.66B
End Cash	$1.71B
Increase/Decrease in Cash	$53.61M
Stock-Based Compensation	$70.15M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.13
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.48
Debt to Equity Ratio	0.94
Gross Margin	81.91%
Operating Margin	23.02%
EBIT Margin	23.02%
EBITDA Margin	--
Pre-Tax Profit Margin	18.99%
Profit Margin	17.65%
Free Cash Flow	$48.67M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.23
Inventory Turnover	2.51
Receiveable Turnover	1.32
Days Sales in Receivables	68.16
Return on Equity	19.16%
Return on Tangible Equity	19.16%
Return on Assets	4.02%
Return on Investments	9.88%
Book Value Per Share	$8.06
Free Cash Flow per Share	$0.35
Operating Cash Flow per Share	$0.51

Data from Zacks Investment Research, Inc.